- Home
- BTBT vs FHTX Comparison
BTBT vs FHTX Comparison
Compare BTBT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBT
- FHTX
- Stock Information
- Founded
- BTBT 2015
- FHTX 2015
- Country
- BTBT United States
- FHTX United States
- Employees
- BTBT N/A
- FHTX N/A
- Industry
- BTBT Finance: Consumer Services
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- BTBT Finance
- FHTX Health Care
- Exchange
- BTBT Nasdaq
- FHTX Nasdaq
- Market Cap
- BTBT 467.0M
- FHTX 517.9M
- IPO Year
- BTBT 2018
- FHTX 2020
- Fundamental
- Price
- BTBT $4.13
- FHTX $7.23
- Analyst Decision
- BTBT Strong Buy
- FHTX Strong Buy
- Analyst Count
- BTBT 2
- FHTX 5
- Target Price
- BTBT $6.50
- FHTX $16.00
- AVG Volume (30 Days)
- BTBT 8.3M
- FHTX 133.0K
- Earning Date
- BTBT 11-12-2024
- FHTX 10-31-2024
- Dividend Yield
- BTBT N/A
- FHTX N/A
- EPS Growth
- BTBT N/A
- FHTX N/A
- EPS
- BTBT 0.27
- FHTX N/A
- Revenue
- BTBT $86,851,522.00
- FHTX $35,185,000.00
- Revenue This Year
- BTBT $192.83
- FHTX N/A
- Revenue Next Year
- BTBT $40.81
- FHTX $15.40
- P/E Ratio
- BTBT $15.34
- FHTX N/A
- Revenue Growth
- BTBT 153.87
- FHTX 61.95
- 52 Week Low
- BTBT $1.76
- FHTX $2.70
- 52 Week High
- BTBT $5.27
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- BTBT 69.21
- FHTX 41.45
- Support Level
- BTBT $2.91
- FHTX $7.24
- Resistance Level
- BTBT $3.52
- FHTX $8.35
- Average True Range (ATR)
- BTBT 0.24
- FHTX 0.57
- MACD
- BTBT 0.09
- FHTX -0.08
- Stochastic Oscillator
- BTBT 99.19
- FHTX 16.02
About BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries.. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. It generates revenue from digital asset mining and ETH staking business.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.